|
|
Vaccine Detail
|
α-GalCer-loaded tumor-cell vaccine |
| Vaccine Information |
- Vaccine Name: α-GalCer-loaded tumor-cell vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007652
- Type: Tumor cell vaccine
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: activated NKT and NK cells contribute to IFN-γ production required for vaccine efficacy, but NKT cells are necessary and sufficient for this process. This data suggest that Foxp3+ Treg depletion together with vaccination permits greater induction of innate (NK cell) and adaptive (CD8+ T cell) activities leading to greater antitumor immunity. vaccination in combination with Treg depletion results in an increase of activated CD8+ T cells in the periphery, which is associated with an increase in CD8+ T cells infiltrating the tumor. (Mattarollo et al., 2013)
|
| References |
Mattarollo et al., 2013: Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunology and cell biology. 2013; 91(1); 105-114. [PubMed: 23090488].
|
|
